Denali Buyout Validates F-star’s Asset-Centric Model
Denali Therapeutics will pay around $470m in upfront and milestone payments to acquire its CNS bispecific antibody development partner F-star Gamma, lending credence to F-star’s business model of individual, asset-specific spin offs.
You may also be interested in...
As it narrows focus to core therapeutic areas ahead of acquiring Shire, Takeda sends uterine fibroid and endometriosis rights to compatriot firm ASKA. Zai Lab and Crescendo team up on antibody candidate for inflammatory indications.
'Asset-centric' bispecific antibody developer F-star has agreed an option deal for a package of immuno-oncology-focused antibodies with Merck of Germany.
Jane Dancer, chief business officer at F-star – a Cambridge, UK-based biotech – chats to Mike Ward, global director of content for Informa Pharma Intelligence, on the sidelines of the recent BIO-Europe partnering conference in Cologne, Germany.